Advertisement
Advertisement

STOK

STOK logo

Stoke Therapeutics, Inc. Common Stock

30.35
USD
Sponsored
-0.72
-2.31%
Jan 30, 16:00 UTC -5
Closed
exchange

After-Market

30.33

-0.02
-0.07%

STOK Earnings Reports

Positive Surprise Ratio

STOK beat 17 of 26 last estimates.

65%

Next Report

Date of Next Report
Mar 16, 2026
Estimate for Q4 25 (Revenue/ EPS)
$5.95M
/
-$0.74
Implied change from Q3 25 (Revenue/ EPS)
-44.04%
/
+13.85%
Implied change from Q4 24 (Revenue/ EPS)
-73.69%
/
+311.11%

Stoke Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 04, 2025, STOK reported earnings of -0.65 USD per share (EPS) for Q3 25, missing the estimate of -0.57 USD, resulting in a -12.13% surprise. Revenue reached 10.63 million, compared to an expected 6.28 million, with a 69.21% difference. The market reacted with a -9.94% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 13 analysts forecast an EPS of -0.74 USD, with revenue projected to reach 5.95 million USD, implying an increase of 13.85% EPS, and decrease of -44.04% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Stoke Therapeutics, Inc. Common Stock reported EPS of -$0.65, missing estimates by -12.13%, and revenue of $10.63M, 69.21% above expectations.
The stock price moved down -9.94%, changed from $25.34 before the earnings release to $22.82 the day after.
The next earning report is scheduled for Mar 16, 2026.
Based on 13 analysts, Stoke Therapeutics, Inc. Common Stock is expected to report EPS of -$0.74 and revenue of $5.95M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement